These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25266748)

  • 41. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
    Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F
    J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
    Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis.
    Kawakami H; Sugioka K; Yonesaka K; Satoh T; Shimomura Y; Nakagawa K
    J Clin Oncol; 2011 Aug; 29(23):e678-9. PubMed ID: 21690478
    [No Abstract]   [Full Text] [Related]  

  • 44. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection.
    Tronconi MC; Sclafani F; Rimassa L; Carnaghi C; Personeni N; Santoro A
    J Clin Oncol; 2011 Aug; 29(23):e680-1. PubMed ID: 21690469
    [No Abstract]   [Full Text] [Related]  

  • 46. [Antibody treatment in colorectal cancer--what the surgeon needs to know].
    Thalheimer A; Illert B; Reimer P; Bueter M; Thiede A; Gasser M; Fein M; Waaga-Gasser AM; Meyer D
    Zentralbl Chir; 2008 Apr; 133(2):101-6. PubMed ID: 18415895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The wide gulf between stage III and stage IV colon cancer.
    Ting DT; Ryan DP
    Lancet Oncol; 2014 Jul; 15(8):785-6. PubMed ID: 24928084
    [No Abstract]   [Full Text] [Related]  

  • 48. Panitumumab in metastatic colorectal cancer.
    Wisinski KB; Mulcahy MF; Benson AB
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):10-1. PubMed ID: 17491586
    [No Abstract]   [Full Text] [Related]  

  • 49. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
    Vijayaraghavan A; Efrusy MB; Göke B; Kirchner T; Santas CC; Goldberg RM
    Int J Cancer; 2012 Jul; 131(2):438-45. PubMed ID: 21898389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
    Berretta M; Martellotta F; Simonelli C; Di Benedetto F; De Ruvo N; Drigo A; Bearz A; Spina M; Zanet E; Berretta S; Tirelli U
    J Chemother; 2007 Jun; 19(3):343-6. PubMed ID: 17594933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
    Landherr L; Nagykálnai T
    Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
    Glynne-Jones R; Mawdsley S; Harrison M
    Acta Oncol; 2010 Apr; 49(3):278-86. PubMed ID: 20180626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Successes in late solid tumors. New therapy offer].
    Arnheim K
    MMW Fortschr Med; 2004 Nov; 146(47):71. PubMed ID: 15624667
    [No Abstract]   [Full Text] [Related]  

  • 56. Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.
    Lieberman R
    Am J Ther; 2012 Nov; 19(6):395-6. PubMed ID: 23011178
    [No Abstract]   [Full Text] [Related]  

  • 57. Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.
    Chu E
    Clin Colorectal Cancer; 2008 May; 7(3):162. PubMed ID: 18621632
    [No Abstract]   [Full Text] [Related]  

  • 58. Blepharitis induced by epidermal growth factor receptor-targeting therapy.
    Ulusakarya A; Gumus Y; Delmas-Marsalet B; Machover D
    Am J Clin Oncol; 2006 Oct; 29(5):531. PubMed ID: 17023793
    [No Abstract]   [Full Text] [Related]  

  • 59. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
    Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
    Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case report and discussion of cetuximab-induced folliculitis.
    Adams DH; Nutt T
    Am J Clin Dermatol; 2006; 7(5):333-6. PubMed ID: 17007545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.